KLS 13023
Alternative Names: KLS-13023Latest Information Update: 03 Jul 2026
At a glance
- Originator Neuropathix
- Class Cannabinoids; Hepatoprotectants; Neuroprotectants; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatic encephalopathy
- No development reported Traumatic brain injuries
Most Recent Events
- 03 Jul 2026 KLS 13023 is still in preclinical studies for Hepatic encephalopathy in USA (PO) (KannaLife Sciences pipeline, July 2026)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Hepatic-encephalopathy in USA (PO, Capsule)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Traumatic-brain-injuries in USA (PO, Capsule)